Ovid Therapeutics Inc. (OVID) Stock Forecast
OVID analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 12 analysts
- Price target
- $6.00 average of analyst targets
- Upside to target
- +179.1% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.08
- 52-week range
- $1.20 – $2.96
OVID analyst ratings
12 analystsNumber of analysts at each rating.
OVID price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
OVID earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.08 | −$0.10 | −$0.05 | −$0.17 | +50.3% | 9 |
| Current fiscal year (2026) | −$0.36 | −$0.41 | −$0.24 | −$0.23 | −57.5% | 9 |
| Next fiscal year (2027) | −$0.37 | −$0.50 | −$0.29 | −$0.36 | −1.2% | 9 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
OVID revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $26,310 | $0 | $200,000 | −80.1% | 13 |
| Current fiscal year (2026) | $791,620 | $700,000 | $1.6M | −89.1% | 13 |
| Next fiscal year (2027) | $325,620 | $0 | $2.0M | −58.9% | 13 |
OVID EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
OVID revenue: reported and forecast
OVID EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.11 | −$0.09 | −$0.09 | −$0.09 | −$0.08 | −20.2% | 5 up · 0 down |
| Current fiscal year (2026) | −$0.44 | −$0.38 | −$0.37 | −$0.37 | −$0.36 | −17.7% | 7 up · 0 down |
| Next fiscal year (2027) | −$0.45 | −$0.39 | −$0.39 | −$0.39 | −$0.37 | −18.8% | 4 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
OVID earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; OVID beat in 8 of 12.
What analysts expect from OVID
12 analysts cover Ovid Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $6.00, 179.1% above the latest close of $2.15. Analysts expect earnings of −$0.36 per share for 2026, −57.5% from a year earlier. For 2027 the average estimate is −$0.37 per share on revenue of $0.3 million. Ovid Therapeutics beat the EPS estimate in 8 of the last 12 quarters.
Related: OVID income statement, OVID key metrics, OVID chart. See the OVID stock overview for the latest quote and news.
OVID forecast FAQ
What is Ovid Therapeutics's price target?
The average analyst price target for Ovid Therapeutics is $6.00, 179.1% above the latest close of $2.15.
Is Ovid Therapeutics a buy, hold or sell?
Of 12 analysts covering Ovid Therapeutics, 12 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Ovid Therapeutics's EPS forecast?
Analysts forecast −$0.36 per share for 2026 (range −$0.41 to −$0.24); for 2027 the estimate is −$0.37.
What is Ovid Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $0.8 million, growth of −89.1%; for 2027 it is $0.3 million.
When does Ovid Therapeutics report earnings?
Ovid Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 before the market opens; the EPS estimate is $-0.08.
Does Ovid Therapeutics usually beat earnings estimates?
Ovid Therapeutics reported EPS at or above the analyst estimate in 8 of the last 12 quarters.